

Financial news for NVO dated on 2020-06-11: The Daily Biotech Pulse: Sorrento Submits EUA Application For Rapid Coronavirus Test, Decision Day For Viela, Lantern Pharma IPO

Financial news for NVO dated on 2020-06-04: Novo Nordisk Reports Weight Loss Of 14.9% In STEP 1 Trial, Says Met Both Primary Endpoints

Financial news for NVO dated on 2020-06-02: The Daily Biotech Pulse: FDA Nod For Roche's Combo Therapy In Liver Cancer, Allena Rips Higher, Pfizer To Invest Up To \$500M In Biotechs

Financial news for NVO dated on 2020-06-01: Stocks That Hit 52-Week Highs On Monday

Financial news for NVO dated on 2020-05-28: Shares of several healthcare companies are trading higher amid market strength. Strength potentially related to coronavirus efforts including testing, vaccine development and treatment measures from several names in the sector.

Financial news for NVO dated on 2020-05-26: 'List of external participants expected at Rose Garden event starting momentarily where @POTUS will announce @MedicareGov patients will be provided with new choices of Part D plans for insulin at no more than \$35 for a month's supply.' -Steve Herman Tweet

Financial news for NVO dated on 2020-05-21: The Daily Biotech Pulse: Mixed Filgotinib Readout For Gilead-Galapagos, Akorn To File For Chapter 11, D-Day For Aquestive

Financial news for NVO dated on 2020-05-20: Stocks That Hit 52-Week Highs On Wednesday

Financial news for NVO dated on 2020-05-18: Novo Nordisk Option Alert: Jan 15 \$75 Calls Sweep (34) near the Ask: 327 @ \$1.351 vs 11 OI; Ref=\$63.9799

Financial news for NVO dated on 2020-05-13: Novo Nordisk Shares Quiet Following Press Release Co.'s Semaglutide 2.4 mg Shows Superior, Sustained Weight Loss vs Placebo

Financial news for NVO dated on 2020-05-06: The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle

Financial news for NVO dated on 2020-05-06: Novo Nordisk Sales Rose by 16% in Q1 2020

Financial news for NVO dated on 2020-04-29: The Daily Biotech Pulse: Inovio's MERS Vaccine Data, Fast Track Designation For Erytech, FDA Approves Higher Dose Of Merck's Keytruda

Financial news for NVO dated on 2020-04-28: Stocks That Hit 52-Week Highs On Tuesday

Financial news for NVO dated on 2020-04-28: The Daily Biotech Pulse: Pfizer Earnings, Roche's Spinal Muscular Dystrophy Treatment, Moderna COVID-19 Vaccine Update

Financial news for NVO dated on 2020-04-27: Stocks That Hit 52-Week Highs On Monday

Financial news for NVO dated on 2020-04-24: The Daily Biotech Pulse: FDA Approves Sanofi's Meningococcal Vaccine, Pluristem Secures \$54M In Funding For COVID-19 Treatment, Oric Pharma Prices IPO

Financial news for NVO dated on 2020-04-23: Stocks That Hit 52-Week Highs On Thursday

Financial news for NVO dated on 2020-04-21: The Daily Biotech Pulse: Applied DNA Begins Validating COVID-19 Test, Cara's Positive Readout, Novan Explores Strategic Alternatives

Financial news for NVO dated on 2020-04-16: Shares of several healthcare companies are trading higher. Strength could potentially be related to the increased demand in medical products stemming from the coronavirus pandemic.

Financial news for NVO dated on 2020-04-09: Novo Nordisk Receives Health Approval For Rybelsus As Treatment Option To Improve Glycemic Control In Adults With Type 2 Diabetes Mellitus

Financial news for NVO dated on 2020-03-30: Shares of several healthcare companies are trading higher as the market rebounds on extended measures to help curb the coronavirus. NOTE: The sector could also be trading higher due to increased demand for medical products amid the coronavirus outbreak.

Financial news for NVO dated on 2020-03-26: Novo Nordisk shares are trading higher, notable above other healthcare names, not currently seeing company-specific news. Markets have been volatile over past few sessions amid US stimulus legislation.

Financial news for NVO dated on 2020-03-25: 20 Healthcare Stocks Moving In

Wednesday's Pre-Market Session

Financial news for NVO dated on 2020-03-23: Shares of several healthcare companies are trading higher the Fed announced actions to support the U.S. economy. The Fed will do open-ended treasury, mortgage-backed securities and will buy \$375 billion in treasury this week.

Financial news for NVO dated on 2020-03-16: Novo Nordisk Pauses The Clinical Trials Investigating Concizumab In Haemophilia A And B With Or Without Inhibitors As A Result Of Non-Fatal Thrombotic Events In Three Patients

Financial news for NVO dated on 2020-03-16: Shares of several healthcare companies are trading lower in sympathy with the overall market on continued downward momentum caused by the coronavirus. The virus has had a negative impact on the global economy.

Financial news for NVO dated on 2020-03-13: Shares of several healthcare companies are trading higher as the market rebounds following Thursday's selloff. NOTE: Since the coronavirus outbreak the healthcare sector has been extremely volatile.

Financial news for NVO dated on 2020-03-12: Shares of several healthcare companies are trading lower as equities sell off amid continued global coronavirus concerns. The virus has caused global economic disruption and negatively impacted stocks across sectors.

Financial news for NVO dated on 2020-03-11: Shares of several healthcare companies are trading lower. Movement appears market related amid selloff in equities. The global coronavirus outbreak has caused volatility in global markets and impacted stocks across sectors.

Financial news for NVO dated on 2020-03-09: 52 Healthcare Stocks Moving In Monday's Pre-Market Session

Financial news for NVO dated on 2020-03-04: Shares of several healthcare-related companies are trading higher after Joe Biden secured several key wins in Super Tuesday. Biden's more 'moderate' healthcare policies have been seen as more favorable for the sector.

Financial news for NVO dated on 2020-03-02: Novo Nordisk Option Alert: Mar 20 \$60 Calls Sweep (2) near the Ask: 500 @ \$2.451 vs 464 OI; Earnings 5/1 Before Open [est] Ref=\$60.09

Financial news for NVO dated on 2020-03-02: Novo Nordisk shares are trading higher, not currently seeing company-specific news. NOTE: Several healthcare stocks are trading higher for the session.

Financial news for NVO dated on 2020-02-24: Shares of several healthcare and biotech companies are trading lower amid continued spread of coronavirus including notable upticks in Iran and Italy. NOTE: The virus has raised fear of a global economic slowdown.

Financial news for NVO dated on 2020-02-06: The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs

Financial news for NVO dated on 2020-02-05: 13 Key NASH Drug Candidates To Watch For In A Potential \$30-Billion Market

Financial news for NVO dated on 2020-02-05: Stocks That Hit 52-Week Highs On Wednesday

Financial news for NVO dated on 2020-02-05: Novo Nordisk shares are trading higher following Q4 results. The company reported a 9% year-over-year increase in overall revenue and a 9.8% increase in diabetes/obesity care revenues.

Financial news for NVO dated on 2020-02-05: The Daily Biotech Pulse: Merck Spins Off Slow-Growth Businesses, ZioPharm Announces Offering, PhaseBio Data

Financial news for NVO dated on 2020-02-05: Earnings Scheduled For February 5, 2020

Financial news for NVO dated on 2020-01-31: Novo Nordisk's Rybelsus Recommended For Approval For Treatment Of Adults With Type-2 Diabetes By European Regulatory Authorities

Financial news for NVO dated on 2020-01-24: Novo Nordisk Reports Partnership With HighRes Biosolutions To Transform Drug Discovery In Automated Lab

Financial news for NVO dated on 2020-01-23: Novo Nordisk Option Alert: Feb 21 \$65 Calls Sweep (6) near the Ask: 1026 @ \$0.497 vs 2637 OI; Earnings 2/5 Before Open Ref=\$61.62

Financial news for NVO dated on 2020-01-17: B of A Securities Reiterates Neutral on Novo Nordisk, Raises Price Target to \$440

Financial news for NVO dated on 2020-01-17: The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares

Financial news for NVO dated on 2020-01-17: Novo Nordisk Confirms That Its Rybelsus Diabetes Pill Will Be Covered by Express Scripts

Financial news for NVO dated on 2020-01-16: Novo Nordisk Says FDA Also Updated Rybelsus Label To Include Additional Information From Pioneer 6 CVOT Demonstrating CV Safety; Says Rybelsus Demonstrated CV Safety By Meeting Primary Endpoint Of Non-inferiority For Composite MACE Endpoint

Financial news for NVO dated on 2020-01-16: Novo Nordisk Announces Ozempic Approved In US For CV Risk Reduction In People With Type 2 Diabetes And Established CVD

Financial news for NVO dated on 2020-01-16: The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves Into Clinics

Financial news for NVO dated on 2020-01-15: Stocks That Hit 52-Week Highs On Wednesday

Financial news for NVO dated on 2020-01-15: Novo Nordisk A/S shares are trading higher on seemingly no company-specific news to justify the price action.

Financial news for NVO dated on 2020-01-15: The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integra Lifesciences Lowers Q4 Guidance

Financial news for NVO dated on 2020-01-15: 34 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Financial news for NVO dated on 2020-01-14: The Daily Biotech Pulse: PhaseBio To Buy Hypertension Asset, Stemline Falls On Q4 Pre-Announcement, FDA Panel To Review Nektar's Opioid Drug

Financial news for NVO dated on 2020-01-10: Stocks That Hit 52-Week Highs On Friday

Financial news for NVO dated on 2020-01-10: Novo Nordisk shares are trading higher. The stock reached a 52-week high today. Not seeing any news to justify the price action.

Financial news for NVO dated on 2020-01-06: FDA Approves Novo Nordisk's Fiasp For Treatment Of Children With Diabetes

Financial news for NVO dated on 2020-01-03: Novo Nordisk shares are trading lower after Guggenheim Securities downgraded the stock from Buy to Neutral.

Financial news for NVO dated on 2020-01-03: Guggenheim Securities Downgrades Novo Nordisk to Neutral

Financial news for NVO dated on 2020-01-02: Novo Nordisk Announces 'My\$99Insulin' Program And Other Insulin Affordability Measures

Financial news for NVO dated on 2020-01-02: 21 Healthcare Stocks Moving In Thursday's Pre-Market Session

Financial news for NVO dated on 2019-12-27: Stocks That Hit 52-Week Highs On Friday

Financial news for NVO dated on 2019-12-26: Novo Nordisk Option Alert: Jan 17 \$60 Calls Sweep (36) near the Ask: 902 @ \$0.5 vs 4805 OI; Earnings 1/31 Before Open [est] Ref=\$58.0899

Financial news for NVO dated on 2019-12-18: The Daily Biotech Pulse: Positive Adcom Verdict For Merck, Homology Medicine Slips On Mixed Gene Therapy Efficacy Data

Financial news for NVO dated on 2019-12-17: The Daily Biotech Pulse: Roche Gets US Antitrust Clearance For Spark Purchase, An Orphan Drug Designation For Prevail, Dynavax Names CEO

Financial news for NVO dated on 2019-12-02: Shares of several healthcare stocks are trading lower as US equities dip following escalating US-China tensions over Hong Kong. US Stocks further fell on worse-than-expected manufacturing data.

Financial news for NVO dated on 2019-11-25: Novo Nordisk shares are trading higher. Not currently seeing any company-specific news.

Financial news for NVO dated on 2019-11-22: Trump Says he Will Release a Plan to Let States Import Prescription Drugs Which are "MUCH CHEAPER"

Financial news for NVO dated on 2019-11-22: 19 Healthcare Stocks Moving In Friday's Pre-Market Session

Financial news for NVO dated on 2019-11-20: Novo Nordisk shares are trading lower. NOTE: The company earlier presented at its 2019 Capital Markets day, giving growth guidance and financial targets.

Financial news for NVO dated on 2019-11-20: 13 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Financial news for NVO dated on 2019-11-20: The Daily Biotech Pulse: Endo's Cellulite Treatment Accepted For Review, Diffusion Pharma Reports Positive Glioblastoma Data

Financial news for NVO dated on 2019-11-20: Novo Nordisk Expects to Meet Its Current Long-term Financial Targets and Introduces Strategic Aspirations at the Capital Markets Day 2019

Financial news for NVO dated on 2019-11-20: Novo Nordisk EVP for Commercial Strategy and Corporate Affairs Says Co Expects to Increase Its Diabetes Market Share to More Than a Third by 2025 From 28% Today

Financial news for NVO dated on 2019-11-19: The Daily Biotech Pulse: Therapix To Reverse Merge With CBD Company, Crispr Gene Editing Therapy Readout

Financial news for NVO dated on 2019-11-18: UBS Downgrades Novo Nordisk to Neutral

Financial news for NVO dated on 2019-11-18: Benzinga's Top Upgrades, Downgrades For November 18, 2019

Financial news for NVO dated on 2019-11-18: Barclays Upgrades Novo Nordisk to Overweight

Financial news for NVO dated on 2019-11-18: Dicerna, Novo Nordisk Enter Agreement to Discover and Develop RNAi Therapies for Liver-Related Cardio-Metabolic Diseases

Financial news for NVO dated on 2019-11-15: The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval

Financial news for NVO dated on 2019-11-12: Novo Nordisk Option Alert: Dec 20 \$60 Calls Sweep (2) near the Ask: 500 @ \$0.801 vs 4043 OI; Ref=\$57.245

Financial news for NVO dated on 2019-11-11: 5 Healthcare Stocks Moving In Monday's Pre-Market Session

Financial news for NVO dated on 2019-11-07: Novo Nordisk Obtains Exclusive Worldwide Licence to Potential NASH Candidate UD-014 From Ube Industries

Financial news for NVO dated on 2019-11-06: Novo Nordisk Earlier Reported DKK15B Buyback

Financial news for NVO dated on 2019-11-01: Novo Nordisk shares are trading higher after the company reported better-than-expected Q3 EPS and sales results.

Financial news for NVO dated on 2019-11-01: 26 Stocks Moving in Friday's Pre-Market Session

Financial news for NVO dated on 2019-11-01: Earnings Scheduled For November 1, 2019

Financial news for NVO dated on 2019-10-31: The Daily Biotech Pulse: Agile Receives Favorable Adcom Verdict, Merit Medical Tumbles On Earnings, 2 Biotechs To Debut

Financial news for NVO dated on 2019-10-30: The Daily Biotech Pulse: Novartis Program Placed On Partial Clinical Hold, Adcom Snub For Amag, Amgen Earnings

Financial news for NVO dated on 2019-10-29: The Daily Biotech Pulse: Mirati Tastes Success With KRAS Inhibitor, Roche-Spark Deal Delayed Further, Morphosys Halts Study

Financial news for NVO dated on 2019-10-28: More Earnings And A Fed Decision In Week Four Of The WeTrader Competition

Financial news for NVO dated on 2019-10-25: The Daily Biotech Pulse: Melinta Crosses FDA Hurdle But Sees Liquidity Pushback, Positive Readout For Aclaris Wart Drug

Financial news for NVO dated on 2019-10-22: FDA Approves Novo Nordisk's Expanded Label For Fiasp To Include Use In Insulin Infusion Pumps For Improving Glycemic Control In Adults With Type 1/Type 2 Diabetes

Financial news for NVO dated on 2019-10-18: Novo Nordisk Option Alert: Nov 15 \$55 Calls Sweep (42) near the Ask: 3000 @ \$0.5 vs 377 OI; Earnings 11/1 Before Open Ref=\$52.33

Financial news for NVO dated on 2019-10-17: 14 Healthcare Stocks Moving In Thursday's Pre-Market Session

Financial news for NVO dated on 2019-10-14: 9 Healthcare Stocks Moving In Monday's Pre-Market Session

Financial news for NVO dated on 2019-10-04: 16 Healthcare Stocks Moving In Friday's Pre-Market Session

Financial news for NVO dated on 2019-09-30: Attention Biotech Investors: Mark Your Calendar For These October PDUFA Dates

Financial news for NVO dated on 2019-09-23: Novo Nordisk to Price New Diabetes Pill at Level With Its Injectable Ozempic Drug

Financial news for NVO dated on 2019-09-20: Shares of several drug companies are trading higher after Senate Majority Leader McConnell suggested a new Democratic drug price reform proposal would be dead on arrival.

Financial news for NVO dated on 2019-09-20: FDA Approves Novo Nordisk's Rybelsus Oral Tablets

Financial news for NVO dated on 2019-09-20: The Daily Biotech Pulse: FDA Approves Merck HIV Drugs, Five Prime CEO Quits, HTG Molecular Announces Secondary Offering

Financial news for NVO dated on 2019-09-19: 18 Healthcare Stocks Moving In Thursday's Pre-Market Session

Financial news for NVO dated on 2019-09-19: UPDATE: Novo Nordisk Says Primary Endpoint, Rate Of Overall Symptomatic Hypoglycaemia In Maintenance Period Of 36 Weeks Which Was Tested For Superiority, Was Numerically Lower But Not Statistically Significant Versus Insulin Glargine U300

Financial news for NVO dated on 2019-09-19: Novo Nordisk Reports Tresiba Showed An Overall Lower Risk Of Hypoglycaemia And Significantly Lower HBA1c When Compared To Insulin Glargine U300 In People With Type 2 Diabetes

Financial news for NVO dated on 2019-09-17: Benzinga's Top Upgrades, Downgrades For September 17, 2019

Financial news for NVO dated on 2019-09-17: 9 Healthcare Stocks Moving In Tuesday's Pre-Market Session

Financial news for NVO dated on 2019-09-17: 25 Stocks Moving in Tuesday's Pre-Market Session

Financial news for NVO dated on 2019-09-17: Novo Nordisk shares are trading higher after Citigroup upgraded the company's stock from Neutral to Buy.

Financial news for NVO dated on 2019-09-17: Citigroup Upgrades Novo Nordisk to Buy

Financial news for NVO dated on 2019-09-16: Medtronic, Novo Nordisk Enter Agreement to Provide Integrated Digital Solutions for People with Diabetes

Financial news for NVO dated on 2019-09-15: The Week Ahead In Biotech: Novo Nordisk And Merck Await FDA Rulings, 2 IPOs On Deck

Financial news for NVO dated on 2019-09-13: Bank of America Reiterates Neutral on Novo Nordisk, Raises Price Target to \$400

Financial news for NVO dated on 2019-09-11: Novo Nordisk A/S shares are trading higher on seemingly no company-specific news. The stock could potentially be rebounding as the stock has been down ~4% over the past few days.

Financial news for NVO dated on 2019-09-10: Shares of several drugmakers are trading lower on news of a drug pricing bill being developed by House Democrats. The proposed bill would set US drug prices based on prices in other wealthy countries.

Financial news for NVO dated on 2019-09-10: Novo Nordisk A/S shares are trading lower on seemingly no company-specific news.

Financial news for NVO dated on 2019-09-10: 22 Healthcare Stocks Moving In Tuesday's Pre-Market Session

Financial news for NVO dated on 2019-09-09: Novo Nordisk shares are trading lower. Not seeing any news to justify the price action.

Financial news for NVO dated on 2019-09-05: The Daily Biotech Pulse: Cheery Results For Sage's Depression Drug, UniQure Offering, Axsome Aces Study Of Headache Drug

Financial news for NVO dated on 2019-08-30: Benzinga's Top Upgrades, Downgrades For August 30, 2019

Financial news for NVO dated on 2019-08-30: 18 Healthcare Stocks Moving In Friday's Pre-Market Session

Financial news for NVO dated on 2019-08-30: Novo Nordisk A/S shares are trading lower after Jefferies downgraded the stock from Hold to Underperform.

Financial news for NVO dated on 2019-08-30: Jefferies Downgrades Novo Nordisk to Underperform

Financial news for NVO dated on 2019-08-28: Attention Biotech Investors: Mark Your Calendar For These September PDUFA Dates

Financial news for NVO dated on 2019-08-22: Novo Nordisk A/S shares are trading higher after the European Commission granted an extension of the indication for Fiasp for the management of diabetes in adolescents and children aged one year and above.

Financial news for NVO dated on 2019-08-22: 12 Healthcare Stocks Moving In Thursday's Pre-Market Session

Financial news for NVO dated on 2019-08-22: Novo Nordisk Announces Fiasp Approved in Europe for the Management of Diabetes in Adolescents and Children Aged One Year and Above

Financial news for NVO dated on 2019-08-22: Novo Nordisk Files Lawsuit Against Mylan for Patent Infringement of Victoza Diabetes Drug

Financial news for NVO dated on 2019-08-16: Shares of healthcare companies are trading higher as US markets rebound from recent weakness following a yield curve inversion, which caused recession fears. Trump also recently announced the US would delay China tariffs, renewing hopes of a trade deal.

Financial news for NVO dated on 2019-08-16: Shares of several large-cap companies are trading higher with the broader market on renewed optimism surrounding US-China trade talks after Donald Trump announced earlier in the week that he would delay additional tariffs on Chinese goods until December.

Financial news for NVO dated on 2019-08-16: Novo Nordisk Faces Suit In Danish Court, Investors Demand 11.8B Danish Crowns In Compensation For Alleged Stock Manipulation

Financial news for NVO dated on 2019-08-14: Shares of several healthcare companies are trading lower in sympathy with the overall market after the spread between the 2-year and 10-year yield curve inverted for the first time since 2007, potentially signaling an oncoming recession.

Financial news for NVO dated on 2019-08-13: Shares of several large-cap companies are trading higher in sympathy with the overall market after the U.S. announced it is excluding and delaying the additional 10% tariff on certain products.

Financial news for NVO dated on 2019-08-09: Novo Nordisk's Operating Profit Increased by 12% in Danish Kroner and by 6% at Constant Exchange Rates in First Six Months of 2019

Financial news for NVO dated on 2019-08-06: Novo Nordisk Buys Factory in North Carolina to Produce Oral Semaglutide, Other Oral Products

Financial news for NVO dated on 2019-08-01: e-Therapeutics Extends Research Collaboration with Novo Nordisk

Financial news for NVO dated on 2019-07-31: 28 Healthcare Stocks Moving In Today's Pre-Market Session

Financial news for NVO dated on 2019-07-23: Novo Nordisk Says Is Committed To Ensuring Patients' Medicine Supplies Are Unaffected Whatever The Outcome Of Brexit

Financial news for NVO dated on 2019-07-12: Shares of several drug manufacturing companies are trading lower, potentially on continued weakness after the Trump Administration on Thursday rolled back a proposal to eliminate rebates from government drug plans.

Financial news for NVO dated on 2019-07-12: Novo Nordisk Reports ESPEROCT For

Treatment Of Hemophilia A In Children, Adults Approved In Canada

Financial news for NVO dated on 2019-07-11: Shares of several drug manufacturing companies are trading lower. The Trump Administration earlier rolled back a proposal to eliminate rebates from government drug plans and commented on continued efforts to lower drug prices.

Financial news for NVO dated on 2019-06-29: The Week Ahead In Biotech: Pending Clinical Readouts In Focus

Financial news for NVO dated on 2019-06-20: Novo Nordisk shares are trading lower after Deutsche Bank downgraded the stock from Buy to Hold.

Financial news for NVO dated on 2019-06-20: Novo Nordisk Today Announced That European Commission Has Granted Marketing Authorisation For ESPEROCT

Financial news for NVO dated on 2019-06-20: Benzinga's Top Upgrades, Downgrades For June 20, 2019

Financial news for NVO dated on 2019-06-20: Deutsche Bank Downgrades Novo Nordisk to Hold

Financial news for NVO dated on 2019-06-18: The Daily Biotech Pulse: PhaseBio Pumped Up, Eiger Exults On Breakthrough Therapy Designation, Biohaven Slips On Stock Sale

Financial news for NVO dated on 2019-06-17: Novo Nordisk Granted FDA Approval For Victoza

Financial news for NVO dated on 2019-06-11: Novo Nordisk's Oral Semaglutide Diabetes Drug Shows No Greater Risk Of Heart Problems And Death Than Placebo; Oral Semaglutide Demonstrates Non-Inferiority To Placebo In Type 2 Diabetes Patients At High Risk Of Heart Problems

Financial news for NVO dated on 2019-06-11: Benzinga's Top Upgrades, Downgrades For June 11, 2019

Financial news for NVO dated on 2019-06-11: Barclays Upgrades Novo Nordisk to Equal-Weight

Financial news for NVO dated on 2019-06-10: Novo Nordisk shares are trading higher after competitor Eli Lilly announced disappointing diabetes treatment results.

Financial news for NVO dated on 2019-05-22: Novo Nordisk Announces That New Data From Its Diabetes Portfolio Will Be Presented At The Upcoming 79th Annual Scientific Sessions Of The American Diabetes Association In San Francisco, California From June 7-11, 2019

Financial news for NVO dated on 2019-05-10: Shares of several healthcare companies are trading lower in sympathy with the overall market. The S&P 500 is trading lower 1%

Financial news for NVO dated on 2019-05-03: The Daily Biotech Pulse: Obseva Reports Positive Endometriosis Drug Trial, Assembly Biosciences Execs Depart, Coherus Settles With Amgen

Financial news for NVO dated on 2019-05-03: Novo Nordisk Reaffirms FY 2019 Guidance

Financial news for NVO dated on 2019-05-03: Novo Nordisk Q1 Sales 29.3B DKK Beats 29.1B Est

Financial news for NVO dated on 2019-04-29: Credit Suisse Upgrades Novo Nordisk A/S Common Stock to Outperform

Financial news for NVO dated on 2019-04-28: Novo Nordisk Announced Victoza Demonstrated Superiority In Reducing Blood Sugar Vs Placebo In Children And Adolescents With Type 2 Diabetes

Financial news for NVO dated on 2019-04-26: Novo Nordisk Reports Received Positive Opinion From European Regulatory Authorities For Esperoct For Treatment Of Hemophilia A

Financial news for NVO dated on 2019-04-23: Shares of several healthcare stocks are trading higher in a potential rebound from last week's selloff. In an upgrade of HCA Healthcare, Raymond James analysts noted the selloff was 'based on legislation that has almost no chance of passing'

Financial news for NVO dated on 2019-04-12: Gilead Sciences, Novo Nordisk Announce Intent to Initiate a Clinical Collaboration in NASH

Financial news for NVO dated on 2019-04-02: FDA Says Announcing A Public Hearing To Discuss Access To Affordable Insulin Products

Financial news for NVO dated on 2019-03-20: Novo Nordisk Files For FDA Approval Of Oral Semaglutide For Blood Sugar Control And Cardiovascular Risk Reduction In Adults With Type 2 Diabetes

Financial news for NVO dated on 2019-03-18: Novo Nordisk Settles U.S. Patent Litigation Case On Victoza With Teva

Financial news for NVO dated on 2019-03-04: US Senator Ron Wyden Says Finance Committee Continuing To Investigate How Major Insulin Manufacturers Set, Increase 'Outrageous Price Of Insulin'

Financial news for NVO dated on 2019-03-04: Novo Nordisk shares are trading lower after Eli Lilly announced it would introduce lower priced insulin.

Financial news for NVO dated on 2019-03-01: Novo Nordisk Reports Filing For Label Update For Fiasp To EMA, FDA Seeking Approval For Use In Children, Adolescents

Financial news for NVO dated on 2019-02-22: US Senate Finance Committee Launches Bipartisan Investigation Into Rising Insulin Prices; Sends Letters To Eli Lilly, Novo Nordisk And Sanofi

Financial news for NVO dated on 2019-02-20: UPDATE: Abbott, Novo Nordisk Partnership Will 'enable insulin data to be shared between Novo Nordisk connected insulin pens and digital health tools compatible(i) with FreeStyle Libre portfolio of products'

Financial news for NVO dated on 2019-02-20: Abbott, Novo Nordisk Report Partnership To Provide Integrated Digital Solution to People with Diabetes Using Insulin

Financial news for NVO dated on 2019-02-19: Novo Nordisk Says Biologics License Application For Esperoct For Treatment Of Adults, Children With Hemophilia A Approved

Financial news for NVO dated on 2019-02-04: Benzinga's Top Upgrades, Downgrades For February 4, 2019

Financial news for NVO dated on 2019-02-04: Handelsbanken Downgrades Novo Nordisk to Accumulate from Buy; Lowers Price Target to DKK 363 from DKK 375

Financial news for NVO dated on 2019-02-01: Attention Biotech Investors: Mark Your Calendar For These February PDUFA Dates

Financial news for NVO dated on 2019-02-01: Novo Nordisk shares are trading higher after the company posted a 6% year-over-year increase in sales within its diabetes/obesity segment and reported a DKK15B buyback, offsetting a Q4 earnings miss.

Financial news for NVO dated on 2019-02-01: Novo Nordisk Earlier Reported DKK15B Buyback

Financial news for NVO dated on 2019-02-01: Novo Nordisk Earlier Reported Q4 EPS \$0.53 Misses \$0.61 Estimate, Sales \$4.552B Miss \$4.74B Estimate

Financial news for NVO dated on 2019-02-01: 35 Stocks Moving In Friday's Pre-Market Session

Financial news for NVO dated on 2019-02-01: Novo Nordisk Q4 Sales DKK29.73B vs DKK29.77B Est

Financial news for NVO dated on 2019-01-29: Exane BNP Paribas Initiates Coverage On Novo Nordisk with Outperform Rating

Financial news for NVO dated on 2019-01-23: Novo Nordisk Reports Its Xultophy Is Now Available In Canada

Financial news for NVO dated on 2018-12-30: The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials

Financial news for NVO dated on 2018-12-26: 6 Valuable Pipeline Drugs With Upcoming Catalysts

Financial news for NVO dated on 2018-12-23: The Week Ahead In Biotech: Focus Shifts To Year-End Clinical Trial Results

Financial news for NVO dated on 2018-12-17: Argenx Co-development Partner Statens Biotechnology Enters into Collaboration with Novo Nordisk to Develop Novel Treatment for Dyslipidaemia

Financial news for NVO dated on 2018-12-14: Morgan Stanley Initiates Coverage On Novo Nordisk with Equal-Weight Rating

Financial news for NVO dated on 2018-12-10: E-therapeutics Announces Research Collaboration Agreement with Novo Nordisk

Financial news for NVO dated on 2018-11-23: Novo Nordisk Earlier Reported In 6-K That Results From Oral Semaglutide Trial Showed Favorable Safety Profile And 'Significant' Reduction In Cardiovascular Death And All-Cause Mortality In Type 2 Diabetes Patients

Financial news for NVO dated on 2018-11-22: Novo Nordisk Announces Oral Semaglutide Demonstrates Greater Reductions In Both HbA1c and Body Weight vs Victoza In Japanese Adults With Type 2 Diabetes

Financial news for NVO dated on 2018-11-19: Novo Nordisk shares are up 2.6% after analysts at JP Morgan upgraded the stock from 'Neutral' to 'Overweight'

Financial news for NVO dated on 2018-11-19: Benzinga's Top Upgrades, Downgrades For November 19, 2018

Financial news for NVO dated on 2018-11-19: 22 Stocks Moving In Monday's Pre-Market Session

Financial news for NVO dated on 2018-11-19: JP Morgan Upgrades Novo Nordisk to Overweight

Financial news for NVO dated on 2018-11-19: JP Morgan Upgrades Novo Nordisk to Overweight from Neutral; Raises Price Target to DKK 340 from DKK 290

Financial news for NVO dated on 2018-11-02: Embark and Novo Nordisk Collaborate to Discover Novel Therapeutics for Obesity and Metabolic Disease

Financial news for NVO dated on 2018-11-01: The Daily Biotech Pulse: AbbVie's Leukemia Drug Trial Meets Endpoint, Denali Strikes Collaboration Deal

Financial news for NVO dated on 2018-11-01: Novo Nordisk Sees Workforce Cut by 1,300 Employees Before the End of 2018

Financial news for NVO dated on 2018-11-01: Earnings Scheduled For November 1, 2018

Financial news for NVO dated on 2018-10-31: Why Aeterna Zentaris Shares Surged On Novo Nordisk-Strongbridge Biopharma Deal

Financial news for NVO dated on 2018-10-31: Q3 Earnings Preview For Novo Nordisk

Financial news for NVO dated on 2018-10-31: Aeterna Zentaris Shares Up 25% Following Deal Between Novo Nordisk, Strongbridge For Rights To MACRILEN; Aeterna Zentaris Receives 15-18% Royalties From Sales Of MACRILEN In US, Canada

Financial news for NVO dated on 2018-10-31: UPDATE: Novo Nordisk Will Leverage And Fund Stonebridge's Rare Endocrine Commercial Field Organization For MACRILEN For Up To Three Years

Financial news for NVO dated on 2018-10-31: UPDATE: Strongbridge Biopharma To Receive Upfront Payment Of \$145M And Tiered Royalties Related To Sales Of MACRILEN Through 2027; Novo Nordisk To Purchase 5.2M Ordinary Shares Of Stonebridge At \$7/Share

Financial news for NVO dated on 2018-10-26: Novo Nordisk Issues Release Highlighting Its Oral Semaglutide Showed Statistically Significant Reductions In HbA1c, Body Weight In People With Long-Duration Type-2 Diabetes Treated With Insulin

Financial news for NVO dated on 2018-10-17: Anthem, HealthCore And Novo Nordisk Launch Study To Understand Effectiveness Of New Type 2 Diabetes Drug, Ozempic

Financial news for NVO dated on 2018-10-16: Sanofi, Novo Nordisk, Lilly Shares Unaffected Amid Report State Of Minnesota Filed Suit Accusing Insulin Manufacturers Of Deceptive Drug Pricing Practices

Financial news for NVO dated on 2018-10-14: The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for NVO dated on 2018-10-12: Novo Nordisk Says Fiasp Is Effective at Controlling Blood Sugar Levels in Children and Adolescents Living With Type 1 Diabetes, When Compared to Conventional Insulin Aspart

Financial news for NVO dated on 2018-10-11: Stocks Which Set New 52-Week Low Yesterday, October 10th

Financial news for NVO dated on 2018-10-10: Stocks Which Set New 52-Week Low

Yesterday, October 9th

Financial news for NVO dated on 2018-10-08: Benzinga's Top Upgrades, Downgrades For October 8, 2018

Financial news for NVO dated on 2018-10-08: 32 Stocks Moving In Monday's Pre-Market Session

Financial news for NVO dated on 2018-10-08: The Week Ahead In Biotech: Conferences, Clinical Trial Results And IPOs

Financial news for NVO dated on 2018-10-08: Bank of America Downgrades Novo Nordisk to Neutral

Financial news for NVO dated on 2018-10-04: Novo Nordisk shares are down 7.4% after Eli Lilly earlier reported positive trial results in its diabetes candidates; Novo Nordisk is seen as a competitor in the diabetes space and fell on the news.

Financial news for NVO dated on 2018-10-04: 26 Stocks Moving In Thursday's Pre-Market Session

Financial news for NVO dated on 2018-10-01: Asterias Biotherapeutics Announces an IP License Agreement with an Affiliate of Novo Nordisk, Asterias to Recieve \$2M Upfront

Financial news for NVO dated on 2018-10-01: Novo Nordisk to Establish California Manufacturing Site for Stem Cell-based Therapies

Financial news for NVO dated on 2018-10-01: Novo Nordisk Announces First Global Launch Of Connected Insulin Pens

Financial news for NVO dated on 2018-10-01: Roche Signs Collaboration Agreement with Novo Nordisk to Expand Access to Therapy Information by Integrating Insulin Data From Connected Pens to Its Open Ecosystem

Financial news for NVO dated on 2018-09-28: Novo Nordisk Announces New Phase 2 Data for Somapacitan Demonstrate Its Potential as an Efficacious Once-weekly Treatment for Childhood Growth Hormone Deficiency

Financial news for NVO dated on 2018-09-23: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for NVO dated on 2018-09-21: Novo Nordisk Option Alert: Oct 19 \$49 Calls at the Ask: 1919 @ \$0.451 vs 2554 OI; Earnings 10/31 Before Open [est] Ref=\$47.68

Financial news for NVO dated on 2018-09-20: Novo Nordisk Says Oral Semaglutide Showed Greater Reductions In HbA1c, Body Weight, Comparable Number Of Adverse Events vs Dulaglutide

Financial news for NVO dated on 2018-09-18: Novo Nordisk Announces Plans to Cut 400 R&D Jobs in Denmark, China; To Establish New Business Development Unit in Cambridge, MA

Financial news for NVO dated on 2018-09-16: The Week Ahead In Biotech (Sept. 16-22): Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for NVO dated on 2018-09-09: The Week Ahead In Biotech: Conferences, Clinical Trial Results, Earnings And IPOs

Financial news for NVO dated on 2018-09-04: Ossianix, Novo Nordisk Report Signing Of Research, Option Deal On Blood Brain Barrier Delivery Technology For Proteins In Diabetes, Other Metabolic Diseases

Financial news for NVO dated on 2018-08-22: Evotec, Novo Nordisk Form Strategic Research Alliance in Diabetes and Obesity; Financial Details Not Disclosed

Financial news for NVO dated on 2018-08-17: Novo Nordisk Acquires Ziylo; Deal Price Could Exceed \$800M

Financial news for NVO dated on 2018-08-09: 85 Biggest Movers From Yesterday

Financial news for NVO dated on 2018-08-08: 68 Stocks Moving In Wednesday's Mid-Day Session

Financial news for NVO dated on 2018-08-08: 40 Stocks Moving In Wednesday's Pre-Market Session

Financial news for NVO dated on 2018-08-08: Earnings Scheduled For August 8, 2018

Financial news for NVO dated on 2018-08-08: Novo Nordisk Shares Fall 4.3% in Premarket; Co Reported Operating Profit Down 8% in First 6 Months of 2018

Financial news for NVO dated on 2018-07-05: A Look At Biotech In 2018 And The Biggest Catalysts Coming Up In The Second Half Of The Year

Financial news for NVO dated on 2018-06-30: The Week Ahead In Biotech: Delayed Clinical Trial Releases In Focus

Financial news for NVO dated on 2018-06-28: Novo Nordisk Announces Oral Semaglutide Shows Superior Reductions in HbA1c and Weight vs Sitagliptin in Long-term Safety and Efficacy Trial, PIONEER 3

Financial news for NVO dated on 2018-06-25: Novo Nordisk Says Tresiba Showed Improved Blood Sugar Control Versus Insulin

Financial news for NVO dated on 2018-06-23: Novo Nordisk Announces Tresiba Demonstrated Significantly Improved Blood Sugar Control and Lower Rates of Hypoglycemia Versus Insulin Toujeo in Real-world Evidence Study at #ADA2018

Financial news for NVO dated on 2018-06-20: Novo Nordisk Oral Semaglutide Shows Statistically Significantly Greater Reductions In HbA1c And Weight Compared To Victoza And Sitagliptin In PIONEER 4 And 7 Trials

Financial news for NVO dated on 2018-06-20: Novo Nordisk Option Alert: Jul 20 \$45 Calls at the Ask: 726 @ \$1.25 vs 1790 OI; Earnings 8/8 Before Open [est] Ref=\$44.86

Financial news for NVO dated on 2018-06-19: Kallyope, Novo Nordisk Report Research Collaboration, Option Agreement To Discover Novel Peptide Therapeutics To Treat Obesity, Diabetes

Financial news for NVO dated on 2018-06-08: 20 Stocks Moving In Friday's Pre-Market Session

Financial news for NVO dated on 2018-06-07: Novo Nordisk Shares Volatile At Close; Co. Considering Laying Off Up To 3K Employees, Dropping Long-Term Financial Targets, Cites Challenging US Market

Financial news for NVO dated on 2018-05-29: Novo Nordisk Says Trial Achieved Primary Objective Demonstrating Statistically Significant And Superior Improvement In HBA1C With Oral Semaglutide vs Empagliflozin At 26 Weeks

Financial news for NVO dated on 2018-05-29: Novo Nordisk Says Oral Semaglutide Shows Superior Improvement In HBA1C vs Empagliflozin In Pioneer 2 Trial

Financial news for NVO dated on 2018-05-24: Novo Nordisk Announces Real-world Evidence Shows Clinically Meaningful Weight Loss in People Receiving Saxenda

Financial news for NVO dated on 2018-05-23: Epigen Biosciences to License its LPA1 Receptor Small Molecule Program to Novo Nordisk for up to \$200M

Financial news for NVO dated on 2018-05-21: Novo Nordisk Reports New Head-To-Head Pharmacokinetic Study Adults With Hemophilia B Who Received Single Dose Of Rebinyn Achieved High Factor IX Activity For Longer Than Those Treated With rFIXFc

Financial news for NVO dated on 2018-05-16: BioLamina, Novo Nordisk Partner to Advance Stem Cell Based Therapies for Three Common Medical Conditions

Financial news for NVO dated on 2018-05-02: Novo Nordisk Reports Q1 Operating Profit DKK12.45B vs DKK11.57B Est

Financial news for NVO dated on 2018-04-18: Novo Nordisk's Xultophy Approved In Canada For The Treatment Of Adults With Type 2 Diabetes

Financial news for NVO dated on 2018-04-13: BMO's Bearish Stance On Eli Lilly Comes To An End

Financial news for NVO dated on 2018-04-05: Novo Nordisk, EpiDestiny Report Novo Obtained Exclusive Global License To Sickle Cell Disease Programme, EPI01

Financial news for NVO dated on 2018-03-26: Novo Nordisk Announces FDA Approves Inclusion of Data on Cardiovascular Outcomes and Severe Hypoglycaemia in the Tresiba

Financial news for NVO dated on 2018-03-22: Novo Nordisk Elects Helge Lund As New Chairman

Financial news for NVO dated on 2018-03-20: Hearing Novo Nordisk Phase 2 Data Presented On Semaglutide Injection Showed Significant Weight Loss In Adults With Obesity

Financial news for NVO dated on 2018-02-27: UPDATE: Novo Nordisk Says Adults Treated Prophylactically With N8-GP Every 4 Days Experienced Median Bleeding Rate Of 1.3 Episodes vs 30.9 Episodes For People Treated On Demand

Financial news for NVO dated on 2018-02-27: Novo Nordisk Filed For Regulatory Approval Of Long-Acting Factor N8-GP In US, EU For Treatment Of Hemophilia A

Financial news for NVO dated on 2018-02-23: Pharma Stock Roundup: AstraZeneca, Merck, AbbVie And More

Financial news for NVO dated on 2018-02-22: 30 Stocks Moving In Thursday's Pre-Market Session

Financial news for NVO dated on 2018-02-09: Novo Nordisk's Ozempic Approved in EU for Treatment of Type 2 Diabetes

Financial news for NVO dated on 2018-02-02: 44 Biggest Movers From Yesterday

Financial news for NVO dated on 2018-02-01: 38 Stocks Moving In Thursday's Mid-Day Session

Financial news for NVO dated on 2018-02-01: 31 Stocks Moving In Thursday's Pre-Market Session

Financial news for NVO dated on 2018-02-01: Earnings Scheduled For February 1, 2018

Financial news for NVO dated on 2018-02-01: Novo Nordisk Shares Fall 5% in Premarket Following Weaker than Expected Q4 Results

Financial news for NVO dated on 2018-01-30: Sanofi On A Buyout Spree This Month: Announces Ablynx Acquisition For \$4.8 Billion

Financial news for NVO dated on 2018-01-23: Pharma M&A Picks Up Momentum

Financial news for NVO dated on 2018-01-23: Biotech M&A Off To A Strong Start In 2018: More Deals To Follow?

Financial news for NVO dated on 2018-01-18: Ablynx 10.2% Shareholder Van Herk Investments Says Novo Nordisk Offer Undervalues Co -Reuters

Financial news for NVO dated on 2018-01-16: Eli Lilly's Risks Could Be Underappreciated, Goldman Sachs Says In Downgrade

Financial news for NVO dated on 2018-01-09: Novo Nordisk Confirms Bid For Ablynx But Faces Rejection

Financial news for NVO dated on 2018-01-09: Novo Nordisk Reports Health Canada Approved Ozempic To Improve Glycemic Control In Adults With Type 2 Diabetes Mellitus

Financial news for NVO dated on 2018-01-08: Ablynx Shares Up 44% Mon. Following Earlier News Co. 'Strongly Believes' EUR28/Share Offer From Novo Nordisk 'Fundamentally Undervalues The Co., Future Prospects'

Financial news for NVO dated on 2018-01-08: A Peek Into The Markets: U.S. Stock Futures Mostly Flat Ahead Of Fed Speakers

Financial news for NVO dated on 2018-01-08: Ablynx NV Says Offer By Novo Nordisk To Acquire Co. Fundamentally Undervalues The Co. And Its Future Prospects, Believes The Proposed Consideration And A Complex Instrument Like A CVR Doesn't Constitute A Basis For Further Discussions At This Time

Financial news for NVO dated on 2018-01-08: Novo Nordisk Proposed to Buy Ablynx for up to EUR30.50/Share in Cash

Financial news for NVO dated on 2018-01-05: Orexigen Struggles As Contrave Commercialization Costs Rise

Financial news for NVO dated on 2017-12-29: The Market In 5 Minutes: Apple Issues Apology, Softbank & Uber, The Year In Cryptos

Financial news for NVO dated on 2017-12-29: Benzinga's Top Upgrades, Downgrades For December 29, 2017

Financial news for NVO dated on 2017-12-29: JP Morgan Upgrades Novo Nordisk to Neutral

Financial news for NVO dated on 2017-12-22: The Companies That Led 2017's Biotech Rally

Financial news for NVO dated on 2017-12-18: Novo Nordisk Option Alert: Jun 15 \$60 Calls Sweep (2) at the Bid: 939 @ \$1.301 vs 113 OI; Ref=\$53.2

Financial news for NVO dated on 2017-12-15: Novo Nordisk Reports CHMP Adopted Position Opinion For Ozempic For Treatment Of Adults With Type 2 Diabetes Mellitus

Financial news for NVO dated on 2017-12-11: Forbes Biotech Reporter Matthew Herper Tweets: Interesting #ASH17: \$SHPG up slightly, \$NVO down just .5%; nothing on \$BIVV. These are the companies that could be hurt by Hemlibra and hemophilia gene therapy.

Financial news for NVO dated on 2017-12-06: Bank of America Upgrades Novo Nordisk, Says High Visibility Growth Offered By GLP-1 Makes Franchise Increasingly Attractive; Could See Share Price Upside With Phase 3 Data In Oral semaglutide

Financial news for NVO dated on 2017-12-06: Bank of America Upgrades Novo Nordisk to Buy

Financial news for NVO dated on 2017-12-06: Benzinga's Top Upgrades, Downgrades For December 6, 2017

Financial news for NVO dated on 2017-12-06: Bank of America Merrill Lynch Upgrades Novo Nordisk to Buy from Neutral -Reuters

Financial news for NVO dated on 2017-12-05: Novo Nordisk Shares Spike As Co. Receives FDA Approval For Semaglutide

Financial news for NVO dated on 2017-12-05: Novo Nordisk Reports Xultophy Shown to be Better Option than Basal-Bolus Insulin Therapy to Manage Type 2 Diabetes by Participants in Dual VII Clinical Trial

Financial news for NVO dated on 2017-12-04: REMINDER: Tuesday Is Estimated FDA PDUFA Date For: Johnson & Johnson for Rilpivirine and In Partnership with GlaxoSmithKline For Dolutegravir, and Novo Nordisk for Semaglutide

Financial news for NVO dated on 2017-12-04: The Week Ahead For December 4: The Biggest Catalysts, Conferences, And Investor Events

Financial news for NVO dated on 2017-12-04: Report Published in Journal of Medical Economics Shows Novo Nordisk's Xultophy Offers Greater Weight Reductions than Iglarlix

Financial news for NVO dated on 2017-12-01: The Market In 5 Minutes: Tax Bill, Bitcoin, 'Today' Show, And More

Financial news for NVO dated on 2017-12-01: Benzinga's Top Upgrades, Downgrades For December 1, 2017

Financial news for NVO dated on 2017-12-01: Morgan Stanley Upgrades Novo Nordisk A/S Common Stock to Overweight

Financial news for NVO dated on 2017-12-01: Morgan Stanley Upgrades Novo Nordisk to Overweight from Equal Weight -Reuters

Financial news for NVO dated on 2017-11-30: Attention Biotech Investors: Mark Your Calendar For These December PDUFA Dates

Financial news for NVO dated on 2017-11-21: Novo Nordisk Announces Health Canada Approval For Update To Victoza

Financial news for NVO dated on 2017-11-06: Adam Feuerstein Tweets: \$NVO sales of women's hormone therapies (including Vagifem) -54% this year due to generic competition. This is \$TXMD future.

Financial news for NVO dated on 2017-11-01: Novo Nordisk CEO Says Still Looking to Make Bolt-On Biopharma Acquisitions -Reuters

Financial news for NVO dated on 2017-11-01: Earnings Scheduled For November 1, 2017

Financial news for NVO dated on 2017-11-01: Novo Nordisk CEO Says Legislation in Some U.S. States to Increase Pricing Transparency May Make It Difficult to Conduct Business -Reuters

Financial news for NVO dated on 2017-10-18: Novo Nordisk Press Release Confirms Positive FDA AdCom Vote In Favor Of Semaglutide Approval

Financial news for NVO dated on 2017-10-18: FDA Panel Shows Support Of FDA Approval For Novo Nordisk's Semaglutide

Financial news for NVO dated on 2017-10-18: SHB Upgrades Novo Nordisk to Buy from Accumulate; Raises PT to DKK 357 from DKK 326

Financial news for NVO dated on 2017-10-16: Novo Nordisk's Semaglutide Was Effective and Not Associated with Risk According to the FDA

Financial news for NVO dated on 2017-09-29: Novo Nordisk Reports Received FDA Approval For Fiasp

Financial news for NVO dated on 2017-09-27: Novo Nordisk's New-Generation Basal Insulin Tresiba Approved in China

Financial news for NVO dated on 2017-09-12: With New CEO In Place, Focus For Teva Pharma Turns To 'Execution'

Financial news for NVO dated on 2017-09-11: A Look At Kare Schultz, The New CEO In Charge Of Teva

Financial news for NVO dated on 2017-09-06: Benzinga's Top Upgrades, Downgrades For September 6, 2017

Financial news for NVO dated on 2017-09-06: The Market In 5 Minutes

Financial news for NVO dated on 2017-09-06: Bank of America Upgrades Novo Nordisk A/S Common Stock to Neutral

Financial news for NVO dated on 2017-09-05: Novo Nordisk Announces Conclusion Of Federal Investigation Into Marketing Practices, Co. Will Pay \$46.5M To Federal Govt. And States, \$12.5M For FDA Related Complaint

Financial news for NVO dated on 2017-09-05: UPDATE: Bloomberg Issues Correction On Earlier Headline, U.S. To Seek \$12.2 Million, Not Billion, From Novo Nordisk

Financial news for NVO dated on 2017-09-05: Hearing The U.S. Seeks \$12.15M From Novo Nordisk In Fraud Suit

Financial news for NVO dated on 2017-09-01: Attention Biotech Investors: September Ushers In Another Slew Of PDUFA Catalysts

Financial news for NVO dated on 2017-08-25: Novo Nordisk Issues Release Confirming Victoza Approved In US As Type-2 Diabetes Treatment Indicated To Reduce The Risk Of 3 Major Adverse Cardiovascular Events

Financial news for NVO dated on 2017-08-16: Novo Nordisk Reports Positive Semaglutide Trial Results

Financial news for NVO dated on 2017-08-16: Shares of Lilly Fall on Positive Novo Nordisk SUSTAIN 7 Trial Results

Financial news for NVO dated on 2017-08-09: Novo Nordisk Reports Operating Profit Rose by 8% in First Six Months of 2017; Shares Up 5.42% @\$43.38 in Premarket

Financial news for NVO dated on 2017-08-01: August PDUFA Dates: Biotech Investors Stay Tuned To A Month Of Plenty

Financial news for NVO dated on 2017-07-26: Watch These 8 Huge Put Purchases In Wednesday Trade

Financial news for NVO dated on 2017-07-25: Benzinga's Option Alert Recap From July 25

Financial news for NVO dated on 2017-07-25: Novo Nordisk Option Alert: Aug 18 \$41 Puts Sweep (28) at the Ask: 746 @ \$1.25 vs 75 OI; Ref=\$42.09

Financial news for NVO dated on 2017-07-05: Novo Nordisk Reports Recall Of Cartridge Holders For Certain NovoPen Echo Devices, Cites Potential Health Risks

Financial news for NVO dated on 2017-06-30: Benzinga's Option Alert Recap From June 30

Financial news for NVO dated on 2017-06-30: Option Alert: Novo Nordisk Sep 41.0 Calls Sweep: 615 @ ASK \$3.20: 615 traded vs 63 OI: Earnings 8/9 Before Open \$43.01 Ref

Financial news for NVO dated on 2017-06-23: Novo Nordisk Reports Positive Patient Response In Semaglutide Phase 2 Trial, Expects Phase 3 Program To Begin In 2018

Financial news for NVO dated on 2017-06-22: Novo Nordisk Expects Feedback From EMA on Victoza Application Shortly

Financial news for NVO dated on 2017-06-21: Novo Nordisk Receives 17-2 Vote from FDA Advisory Committee that Victoza Provides Substantial Evidence of Cardiovascular Risk Reduction in Patients with Tpe 2 Diabetes

Financial news for NVO dated on 2017-06-14: Novo Nordisk +2.8% Premarket @\$45.15 on Light Trading; Co Announced Submitted EU Application for Tresiba Including Data from Devote Trial

Financial news for NVO dated on 2017-06-14: Novo Nordisk Submits EU Application for Tresiba

Financial news for NVO dated on 2017-06-12: Novo Nordisk Announces Tresiba Showed No Increased Risk Of Major Cardiovascular Events, Significant Reduction In Rates Of Severe Hypoglycaemia vs Insulin Glargine

Financial news for NVO dated on 2017-06-12: Companies Holding Analyst/Investor Days Today Include Novo-Nordisk and Advaxis

Financial news for NVO dated on 2017-06-11: Novo Nordisk Reports Data Show Switching to Tresiba Provides Significant Reductions in Blood Glucose, Lower Rates of Hypoglycaemia in Real-world Setting

Financial news for NVO dated on 2017-06-06: Novo Nodisk Reports European Commission Has Granted Marketing Authorization For Refixia

Financial news for NVO dated on 2017-06-02: 22 Stocks Moving In Friday's Pre-Market Session

Financial news for NVO dated on 2017-05-31: Novo Nordisk Reports Received FDA Approval of REBINYN

Financial news for NVO dated on 2017-05-27: Novo Nordisk Submits Supplemental Application to FDA for Including Data from Devote Trial in Tresiba Label

Financial news for NVO dated on 2017-05-24: Q1 Seasonality In The Pharma/Biotech Space: What It Is, Why It Happens And Who Is Affected

Financial news for NVO dated on 2017-05-07: Will TherapeuticsMD's Yuvvexy Pass The FDA Muster?

Financial news for NVO dated on 2017-05-03: 20 Biggest Mid-Day Gainers For Wednesday

Financial news for NVO dated on 2017-05-03: Novo Nordisk Launches Xultophy Insulin In The United States

Financial news for NVO dated on 2017-05-03: 25 Stocks Moving In Wednesday's Pre-Market Session

Financial news for NVO dated on 2017-05-03: Novo Nordisk Announced Increased Operating Profit By 10% in First Three Months of 2017; Shares up 6.6% @\$41.50 Premarket

Financial news for NVO dated on 2017-04-28: Business Insider Reporting, 'Novo Nordisk has been accused of engaging in a 'white coat marketing scheme' to sell diabetes drugs'

Financial news for NVO dated on 2017-04-25: Mark Your Calendar For These Days In May To Play The Volatility Around FDA Decision Dates

Financial news for NVO dated on 2017-04-03: Novo's Once-weekly Semaglutide Shows Consistent Bloodglucose Reductions; Results Presented at Endo 2017

Financial news for NVO dated on 2017-03-31: FDA Briefing Document for Novo Nordisk BLA 125611 Coagulation Factor IX (Recombinant), GlycoPEGylated N9-GP

Financial news for NVO dated on 2017-03-31: Novo Nordisk Announces FDA Posts Briefing Materials Prior to Advisory Committee Meeting for Nonacog Beta Pegol, a Long-acting Factor IX for Treatment of Haemophilia B

Financial news for NVO dated on 2017-03-29: Novo Nordisk Reports Resubmission of NDA for Fast-Acting Insulin Aspart in US

Financial news for NVO dated on 2017-03-27: Novo Nordisk Launches Fiasp in Canada for Treatment of Diabetes in Adults

Financial news for NVO dated on 2017-03-24: Novo Nordisk Receives Positive Opinion From European Regulatory Authorities For Refixia

Financial news for NVO dated on 2017-03-24: Novo Nordisk Says CHMP Provides Positive

Opinion For EU Label Update For Tresiba Based On Data From Switch Trials, Demonstrated Clinically Relevant Reductions In Hypoglycaemia Compared With Insulin Glargine U100

Financial news for NVO dated on 2017-03-23: Novo Nordisk CEO Says Looking At External Innovation But Won't Turn Co. Into 'Big M&A Machine'

Financial news for NVO dated on 2017-03-23: Companies Holding Annual Shareholder Meetings Today Include: KalVista Pharma, Novo Nordisk, Verifone, Stellar Biotech, & Ciena

Financial news for NVO dated on 2017-03-16: CVS Health Launches Reduced Rx Savings Program With Novo Nordisk Participating In The Saving Program

Financial news for NVO dated on 2017-03-10: Adam Feuerstein Weighs In On Novo-GBT Rumors, Undue Sarepta Volatility, Unprofitable Business Of Curing Disease

Financial news for NVO dated on 2017-03-10: Feuerstein on Recent Global Blood Therapeutics Rumor: Says 'Kind of Fits in with [Novo's] Strategic' Angling, Says He's Liked GBT for a Long Time Now, Cites Data for Lead Drug in Sick Cell

Financial news for NVO dated on 2017-03-10: Wall Street's M&A Chatter From March 9

Financial news for NVO dated on 2017-03-09: Biotech Reporter Adam Feuerstein Will Be On Benzinga's PreMarket Prep Friday Morning

Financial news for NVO dated on 2017-03-09: Novo Nordisk CEO Says Looking at Deals in Low Billions of Dollars; Declines Comment on GBT Rumor -Reuters

Financial news for NVO dated on 2017-03-09: Global Blood Therapeutics Spikes to High of \$36.28 on Renewed Takeover Chatter Involving Novo Nordisk

Financial news for NVO dated on 2017-03-09: Wall Street's M&A Chatter From March 8

Financial news for NVO dated on 2017-03-08: EP Vantage Journalist Jacob Plieth Tweets: Hearing rumour that Morgan Stanley might advise \$NVO on \$GBT deal. Board has authorised \$NVO CEO to bid up to \$45.

Financial news for NVO dated on 2017-03-08: Global Blood Shares Halted on Circuit Breaker Amid Report Novo Nordisk Approached Co.

Financial news for NVO dated on 2017-02-02: 18 Biggest Mid-Day Losers For Thursday

Financial news for NVO dated on 2017-02-02: 22 Stocks Moving In Thursday's Pre-Market Session

Financial news for NVO dated on 2017-02-02: Teva Files ANDA With FDA To Seek Generic Version Of Victoza Injection

Financial news for NVO dated on 2017-01-30: Recent Weakness In Eli Lilly, Novo Nordisk, Sanofi Due To New York Times Reporting Drug Makers Accused Of Fixing Drug Prices On Insulin

Financial news for NVO dated on 2017-01-30: Novo Nordisk Announces Collaboration With University of Oxford on Type 2 Diabetes, Invests \$115M in New Research Centre

Financial news for NVO dated on 2017-01-12: Novo Nordisk -3.1% Premarket @\$34.55; Class Action Lawsuit Filed Against Co Claiming Inflated Earnings and Forecasts Due to Price Fixing of Insulin Drugs

Financial news for NVO dated on 2017-01-12: Bernstein Litowitz Berger & Grossmann LLP Announces Securities Class Action Suit Filed Against Novo Nordisk, Certain of its Senior Executives

Financial news for NVO dated on 2017-01-10: Novo Nordisk Reports European Commission Has Granted Marketing Authorization For FIASP For Diabetes Treatment In Adults

Financial news for NVO dated on 2016-12-21: Jim Cramer Shares His Thoughts On Groupon And Novo Nordisk

Financial news for NVO dated on 2016-12-19: Novo Nordisk Reports Received FDA Approval of Tresiba for Use in Children, Adolescents with Diabetes

Financial news for NVO dated on 2016-12-19: Jefferies' 2017 Global Pharma Outlook

Financial news for NVO dated on 2016-12-15: A Primer On NASH

Financial news for NVO dated on 2016-12-06: Novo Nordisk Shares Spike Higher Following Mid-Day Upgrade from Sell to Buy by UBS

Financial news for NVO dated on 2016-12-06: Novo Nordisk Shares Up ~\$0.60 Over Last Min, Now Up 1.7% for Session

Financial news for NVO dated on 2016-12-06: Novo Nordisk Volume Spike

Financial news for NVO dated on 2016-12-05: Novo Nordisk Files for Regulatory Approval of Once-Weekly Semaglutide with the FDA for the Treatment of Type 2 Diabetes

Financial news for NVO dated on 2016-12-05: Novo Nordisk Files for Regulatory Approval of Once-weekly Semaglutide in US, EU for Treatment of Type 2 Diabetes

Financial news for NVO dated on 2016-12-02: Novo Nordisk Announces Xultophy Demonstrates Similar Glucose Control With Reduced Risk of Hypoglycaemia and Superior Weight Profile vs Basal-bolus Therapy

Financial news for NVO dated on 2016-11-30: Novo Nordisk + 4% Preamarket @\$33.99; Co Presenting Today at Piper Jaffray Healthcare Conference

Financial news for NVO dated on 2016-11-29: UPDATE: Novo Nordisk Says Trial of Tresiba Met Primary Endpoint

Financial news for NVO dated on 2016-11-29: Novo Nordisk Announces Tresiba Showed Safe Cardiovascular Profile, Reduces Risk of Severe Hypoglycaemia vs Insulin Glargine

Financial news for NVO dated on 2016-11-22: Novo Nordisk Prices of Xultophy Will be 20 Percent Cheaper Than Tresiba, Victoza Price

Financial news for NVO dated on 2016-11-21: Novo Nordisk Reports Received FDA Approval for Xultophy 100/3.6

Financial news for NVO dated on 2016-11-18: Stocks Hitting 52-Week Lows

Financial news for NVO dated on 2016-11-12: Novo Nordisk Announces Tresiba Demonstrated Lower Day-to-day and Within-day Variability in Glucose-lowering Effect vs Insulin Glargine U300

Financial news for NVO dated on 2016-11-11: Hearing Intereconomia Reporting Novartis To Acquire AstraZeneca

Financial news for NVO dated on 2016-11-11: Novo Nordisk Receives Positive Opinion From EU Regulatory Authorities For Fiasp For Diabetes Treatment

Financial news for NVO dated on 2016-11-10: Novo Nordisk Reports Submission of Application in EU for Including Data from Two SWITCH Trials in Tresiba Label

Financial news for NVO dated on 2016-11-01: Senator Bernie Sanders Tweets: People are dying or getting sicker because they can't afford their insulin, just so Eli Lilly and Novo Nordisk can make outrageous profits.

Financial news for NVO dated on 2016-10-31: Benzinga's Top Downgrades

Financial news for NVO dated on 2016-10-31: Citigroup Downgrades Novo Nordisk A/S Common Stock to Neutral

Financial news for NVO dated on 2016-10-28: Mid-Afternoon Market Update: Crude Oil Down Over 2%; McKesson Shares Drop On Downbeat Earnings

Financial news for NVO dated on 2016-10-28: 18 Biggest Mid-Day Losers For Friday

Financial news for NVO dated on 2016-10-28: Mid-Day Market Update: Integer Gains On Earnings Beat; Senomyx Shares Slide

Financial news for NVO dated on 2016-10-28: Worst Performing Industries For October 28, 2016

Financial news for NVO dated on 2016-10-28: Stocks Hitting 52-Week Lows

Financial news for NVO dated on 2016-10-28: Mid-Morning Market Update: Markets Mostly Higher; Mastercard Beats Q3 Views

Financial news for NVO dated on 2016-10-28: Bank of America Downgrades Novo Nordisk A/S Common Stock to Underperform

Financial news for NVO dated on 2016-10-28: 18 Stocks Moving In Friday's Pre-Market Session

Financial news for NVO dated on 2016-10-28: Novo Nordisk Sheds \$15 Billion In Market Value Following Warning Of Significant Challenges

Financial news for NVO dated on 2016-10-28: Novo Nordisk -16% Premarket @\$34.42 as Company Provides Cautious Guidance on US Market

Financial news for NVO dated on 2016-10-28: Novo Nordisk Says Market Environment in US has become Significantly More Challenging, Negatively Impacting Future Pricing for Company's Products

Financial news for NVO dated on 2016-10-28: Novo Nordisk Reports Q3 EPS \$0.58 vs \$0.56 Est; Revenue \$4.13B vs \$4.12B Est

Financial news for NVO dated on 2016-10-28: Earnings Scheduled For October 28, 2016

Financial news for NVO dated on 2016-10-25: Novo Nordisk Submits Application to FDA, EMA to Include LEADER Data in Victoza Label

Financial news for NVO dated on 2016-10-12: Stocks Hitting 52-Week Lows

Financial news for NVO dated on 2016-10-09: Novo Nordisk Receives CRL from FDA for Faster-acting Insulin Aspart

Financial news for NVO dated on 2016-09-29: Novo Nordisk Announces Plans to Reduce Workforce by ~1,000 Employees; ~50% of Layoffs in Denmark

Financial news for NVO dated on 2016-09-26: vTv Therapeutics Shares Initiated With Buy Rating, \$13 Target

Financial news for NVO dated on 2016-09-23: PiperJaffray Initiates Coverage on Novo-Nordisk at Neutral

Financial news for NVO dated on 2016-09-20: NASH Sympathy Plays On Tobira Therapeutics Deal

Financial news for NVO dated on 2016-09-16: Novo Nordisk Announces Semaglutide Reduced Major Cardiovascular Events By 26% In Adults With Type 2 Diabetes At High Cardiovascular Risk

Financial news for NVO dated on 2016-09-14: The Market In 5 Minutes: Huge FDA News, Major Mid-Week M&A

Financial news for NVO dated on 2016-09-14: Exane BNP Paribas Upgrades Novo-Nordisk to Outperform

Financial news for NVO dated on 2016-09-12: 12 Biggest Mid-Day Gainers For Monday

Financial news for NVO dated on 2016-09-12: Benzinga's Top Upgrades

Financial news for NVO dated on 2016-09-12: Deutsche Bank Upgrades Novo-Nordisk to Buy

Financial news for NVO dated on 2016-09-11: Barron's Picks And Pans: Vodafone, BorgWarner, Novo Nordisk And More

Financial news for NVO dated on 2016-09-09: Benzinga's Top Downgrades

Financial news for NVO dated on 2016-09-09: JP Morgan Downgrades Novo-Nordisk to Neutral

Financial news for NVO dated on 2016-09-08: Novo Nordisk Issues Voluntary Recall Of 6 Batches Of Glucagen Hypokit Due To Detached Needles, Estimates 71,215 Pens Being Recalled; Not Aware Of Any Known Adverse Events Resulting From Recall

Financial news for NVO dated on 2016-09-01: UPDATE: Novo Nordisk CEO Says Questions if it Makes Sense to Produce Fifth-gen Insulin Analogues

Financial news for NVO dated on 2016-09-01: Novo Nordisk CEO Says Pricing Environment in US Becoming More Difficult for Pharmaceutical Companies -Reuters

Financial news for NVO dated on 2016-09-01: Lars Rebien Sorensen to Retire as CEO of Novo Nordisk; Lars Fruergaard Jorgensen Named Successor

Financial news for NVO dated on 2016-08-31: Benzinga's Top Upgrades

Financial news for NVO dated on 2016-08-31: HSBC Upgrades Novo-Nordisk to Hold

Financial news for NVO dated on 2016-08-12: Stocks Hitting 52-Week Lows

Financial news for NVO dated on 2016-08-08: 12 Biggest Mid-Day Losers For Monday

Financial news for NVO dated on 2016-08-08: Worst Performing Industries For August 8, 2016

Financial news for NVO dated on 2016-08-08: Bank of America Downgrades Novo-Nordisk to Neutral

Financial news for NVO dated on 2016-08-05: Earnings Scheduled For August 5, 2016

Financial news for NVO dated on 2016-07-26: Novo Nordisk +1.9% Premarket @ \$56.36; Nordea Markets in Note to Clients, Said Diabetes Treatment Victoza Likely Will Re-enter Medicare Plans at Express Scripts

Financial news for NVO dated on 2016-07-04: Novo Nordisk Invests \$60M in Expanded Production Plant in Kalundborg

Financial news for NVO dated on 2016-06-21: Novo A/S Names Kasim Kutay as New CEO

Financial news for NVO dated on 2016-06-17: Novo Nordisk Vol Spike; Gaps Down to Low of \$51.33

Financial news for NVO dated on 2016-06-15: Lesson Learned: Don't Trust Twitter Users With A Multi-Billion-Dollar Secret

Financial news for NVO dated on 2016-06-14: Jefferies Shares Pharma Stock Catalyst Outlook

Financial news for NVO dated on 2016-06-14: Worst Performing Industries For June 14, 2016

Financial news for NVO dated on 2016-06-13: Novo Nordisk Announces: Faster-Acting Insulin Aspart Showed A Statistically Significant Reduction In HbA1C In Type 1 Diabetes And A Comparable HbA1C Reduction In Type 2 Diabetes Versus Novorapid at ADA

Financial news for NVO dated on 2016-06-12: Novo Nordisk Announces Tresiba Demonstrated Significantly Lower Rates of Overall, Nocturnal and Severe Hypoglycaemia vs Insulin Glargine U-100 at the American Diabetes Association 76th Scientific Sessions

Financial news for NVO dated on 2016-06-02: Novo Nordisk Says Three-Year Data Show Early Response to Saxenda Resulted In Improvements In Weight Loss, Cardiometabolic Risk Factors -Reuters

Financial news for NVO dated on 2016-06-02: Novo Nordisk Shows Three-Year Data Demonstrated Early Response to Saxenda Which Resulted in Improved Weight Loss, Cardiometabolic Risk

Financial news for NVO dated on 2016-05-25: Novo Nordisk's Ideglira Receives Unanimous 16-0 Vote in Favor of Approval from FDA Advisory Committee

Financial news for NVO dated on 2016-05-24: Novo Nordisk's Ideglira Receives 16-0 Vote in Favor of Approval from FDA Panel

Financial news for NVO dated on 2016-05-20: FDA Staff Review of Novo Nordisk Diabetes Drug Showed Inadequate Dosing of Insulin in the Studies Could Have Biased the Estimate of Efficacy in Favor of Combination Product -Reuters

Financial news for NVO dated on 2016-05-16: Novo Nordisk Files for US Regulatory Approval of Long-Acting Factor IX for Treatment of Haemophilia B

Financial news for NVO dated on 2016-04-29: Earnings Scheduled For April 29, 2016

Financial news for NVO dated on 2016-04-28: Novo Nordisk +3% Premarket @\$56.99 Following Report Semaglutide Significantly Reduces Risk of Major Adverse Cardiovascular Events in the SUSTAIN 6 Trial

Financial news for NVO dated on 2016-04-28: UPDATE: Novo Nordisk Expects to File Semaglutide for Regulatory Review in US and EU in Q4 of 2016.

Financial news for NVO dated on 2016-04-28: Novo Nordisk Report Semaglutide Significantly Reduces Risk of Major Adverse Cardiovascular Events in the SUSTAIN 6 Trial

Financial news for NVO dated on 2016-04-06: SocGen Picks New Favorites In Big Pharma

Financial news for NVO dated on 2016-04-06: WHO Says Number of Adults with Diabetes has Quadrupled Since 1980 -AFP

Financial news for NVO dated on 2016-04-02: Novo Nordisk Says Phase 3A Clinical Trial For Semaglutide Once-Weekly Demonstrated Significantly Improved Glycaemic Control

Compared To Placebo In Adults With Type 2 Diabetes

Financial news for NVO dated on 2016-04-02: Novo Nordisk Reports Victoza Provided Superior HbA1c Reductions in Adults with Type 2 Diabetes Compared to Continued Sitagliptin Treatment

Financial news for NVO dated on 2016-03-29: Citi Downgrades Novartis Following SAG Investigation

Financial news for NVO dated on 2016-03-04: Novo Nordisk Says Victoza Significantly Reduces Risk of Major Adverse Cardiovascular Events in Leader Trial ; Says Safety Profile of Victoza in Leader Was Generally Consistent With Previous Liraglutide Clinical Studies

Financial news for NVO dated on 2016-02-23: UPDATE: Novo Nordisk Says Trial Met Primary End-Point by Demonstrating Non-Inferiority in Rate of Severe or Blood Glucose Confirmed Symptomatic Hypoglycemia of Tresiba vs Insulin Glargine

Financial news for NVO dated on 2016-02-19: NovoNordisk Spikes to High of \$50.71 on Volume

Financial news for NVO dated on 2016-02-15: Goldman Sachs Upgrades Novo-Nordisk to Conviction Buy

Financial news for NVO dated on 2016-02-08: Benzinga's Top Downgrades

Financial news for NVO dated on 2016-02-08: UBS Downgrades Novo-Nordisk to Sell

Financial news for NVO dated on 2016-02-04: Worst Performing Industries For February 4, 2016

Financial news for NVO dated on 2016-02-03: Novo Nordisk Lowers Target for Long-Term Operating Profit Growth from 15% to 10%

Financial news for NVO dated on 2016-01-29: Novo Nordisk Announces Tresiba Showed Significantly Lower Rate of Hypglycaemia vs. Insulin Glargine in Phase 3b Trial

Financial news for NVO dated on 2016-01-26: Oddo Securities Upgrades Novo-Nordisk to Buy, Expects European EPS To Grow, Expects Co To Outperform Peers

Financial news for NVO dated on 2016-01-07: Novo Nordisk Files for Regulatory Approval Of Long-Acting Factor IX in EU for Treatment of Haemophilia B

Financial news for NVO dated on 2015-12-17: Early Global News: Obama Meets Bloomberg, Microsoft Supplying Chinese Government With Windows 10, And More

Financial news for NVO dated on 2015-12-17: Novo Nordisk Fourth Phase 3a Trial with Semaglutide in People with Type 2 Diabetes Shows Drug Safe, Well-Tolerated

Financial news for NVO dated on 2015-12-09: Novo Nordisk Submits NDA to FDA for Faster-Acting Insulin Aspart for Treatment of Type 1, 2 Diabetes

Financial news for NVO dated on 2015-12-04: Novo Nordisk Files for Regulatory Approval of Faster-Acting Insulin Aspart EU to Treat Type 1, Type 2 Diabetes; Expects to File NDA With FDA Before Year-End 2015

Financial news for NVO dated on 2015-12-02: Wedbush Reiterates Outperform Rating, \$6 Target on Xoma Following News Co. Licensed XMeta for Diabetes to Novo Nordisk

Financial news for NVO dated on 2015-12-01: Novo Nordisk Says Tests Show Victoza Provides Greater HbA1c Reduction, Improved Likelihood of Reaching Glycaemic Goals Compared to Sglt-2 Inhibitors -Reuters

Financial news for NVO dated on 2015-12-01: Hearing Novo Nordisk Has Said Tests Showing Victoza Demonstrates Greater HbA1c Reduction, Improved Likelihood of Achieving Glycaemic Goals vs. SGLT-2 Inhibitors

Financial news for NVO dated on 2015-12-01: XOMA Reports Licensing Deal with Novo Nordisk for XMeta Program in Diabetes

Financial news for NVO dated on 2015-11-25: Ablynx Announces Nanobody Drug Discovery Collaboration, Licence Agreement With Novo Nordisk

Financial news for NVO dated on 2015-11-05: Novo Nordisk +4% Premarket Following Announcement of Sanofi Diabetes License Agreement With Hanmi

Financial news for NVO dated on 2015-11-04: Hearing Novo Nordisk Has Said Data Presented on Saxenda Showed Significant, Sustained Weight Loss Over Three Years vs. Placebo

Financial news for NVO dated on 2015-10-15: Emisphere Signs License Agreement With Novo Nordisk to Develop Oral Formulations of Four Molecules Targeting Metabolic Indications and Amends GLP-1 Agreement

Financial news for NVO dated on 2015-09-25: UPDATE: Tresiba, Ryzodeg Manufactured by Novo Nordisk

Financial news for NVO dated on 2015-09-25: FDA Approves Two New Drug Treatments For Diabetes Mellitus

Financial news for NVO dated on 2015-09-25: Novo Nordisk Spikes Higher

Financial news for NVO dated on 2015-09-25: Novo Nordisk Says Second Phase 3A Trial With Semaglutide in People With Type 2 Diabetes Achieved Objective

Financial news for NVO dated on 2015-09-16: Novo Nordisk Says Victoza Provides Significantly Greater HbA1c Reduction Than Lixisenatide in New Clinical Trial

Financial news for NVO dated on 2015-09-15: Novo Nordisk Says New Xultophy Phase 3B Trial Shows Improvements In Patient-Reported Outcomes vs Insulin Glargine -Reuters

Financial news for NVO dated on 2015-09-15: Novo Nordisk Says New Data On Saxenda Show Early Response Predicts Improvements In Weight Los, Cardiometabolic Risk Factors -Reuters

Financial news for NVO dated on 2015-09-15: Novo Nordisk Says New Data Confirm Tresiba U200 Delivers Significantly Lower Rates Of Confirmed Hypoglycaemia vs Insulin Glargine U100 -Reuters

Financial news for NVO dated on 2015-09-03: Novo Nordisk Invests \$76M in Raw Material Warehouse in Hillerod, Denmark -Reuters

Financial news for NVO dated on 2015-08-28: Benzinga's Top Initiations

Financial news for NVO dated on 2015-08-28: Leerink Initiates Coverage on Novo-Nordisk at Market Perform

Financial news for NVO dated on 2015-08-27: Novo Nordisk Announces Purchase of Calibrium, No Terms Disclosed

Financial news for NVO dated on 2015-08-26: Novo Nordisk Announces Will Begin Phase 3a Development of Oral Semaglutide

Financial news for NVO dated on 2015-08-24: Novo Nordisk Completes Second And Final Phase 3A Trial With Liraglutide As Adjunct Therapy To Insulin For People With Type 1 Diabetes

Financial news for NVO dated on 2015-08-14: Jim Simons Betting On Microsoft, Colgate-Palmolive, Novo Nordisk & Alaska Air

Financial news for NVO dated on 2015-08-14: US Stock Futures Slip Ahead Of Economic Data

Financial news for NVO dated on 2015-08-14: Genmab Enters Commercial License Agreement with Novo Nordisk for DuoBody Technology

Financial news for NVO dated on 2015-07-16: Novo Nordisk Reports Received FDA Approval for FlexPro PenMate for People with Growth Hormone-Related Diseases

Financial news for NVO dated on 2015-07-15: 5 NYSE Healthcare Stocks With The Highest ROI

Financial news for NVO dated on 2015-07-01: Novo Nordisk to to Stop Distribution of Once-Daily Basal Insulin Tresiba in Germany Following Failure of Price Negotiations With GKV-Spitzenverband -Reuters

Financial news for NVO dated on 2015-06-25: Conquering Hemophilia: Novo Nordisk Reports Encouraging Data From Phase III Trial Of NovoEight

Financial news for NVO dated on 2015-06-24: Novo Nordisk Says in Phase 3 Trial, Novoeight Provided Long-Term Efficacy, Safety in Prophylaxis, Treatment of Bleeds in People With Haemophilia A

Financial news for NVO dated on 2015-06-22: 5 NYSE Healthcare Stocks With The Highest ROE

Financial news for NVO dated on 2015-06-01: 5 NYSE Healthcare Stocks With The Highest Operating Margin

Financial news for NVO dated on 2015-05-22: Novo Nordisk Says Treatment With Saxenda For 3 Years Reduced Risk of Developing Type 2 Diabetes Compared With Placebo

Financial news for NVO dated on 2015-05-22: CHMP Gave Six Recommendations on Extensions of Therapeutic Indication for: Janssen's Simponi and Stelara, Pharmacoclics' Imbruvica, Eisai's Fycompa, BioMarin's Kuvan, Novo's Xultophy

Financial news for NVO dated on 2015-05-20: Novo Sells License On Autoimmune Disease To Janssen

Financial news for NVO dated on 2015-05-18: Baxter International Cites Novo Nordisk As Respondents In USITC Investigation For Violation Of Section 337 Of Certain Recombinant Factor VIII Products

Financial news for NVO dated on 2015-04-30: Novo Nordisk CFO: U.S. Obesity Market Must Emerge, But It Will Take Time

Financial news for NVO dated on 2015-04-30: Novo Nordisk Posts Rise In Profit

Financial news for NVO dated on 2015-04-22: Novo Nordisk Will Repurchase Shares

Financial news for NVO dated on 2015-04-15: SocGen Initiates Big Drug/Pharma Names

Financial news for NVO dated on 2015-04-13: Top 4 Stocks In The Drug Manufacturers-Other Industry With The Highest Dividend Yield

Financial news for NVO dated on 2015-04-07: U.S. FDA Accepts Resubmission Review Of Novo Nordisk's Tresiba, Ryzodeg

Financial news for NVO dated on 2015-04-07: Novo Nordisk Says FDA Accepts Tresiba, Ryzodeg Resubmissions for Review

Financial news for NVO dated on 2015-03-31: Top First Quarter European ETFs

Financial news for NVO dated on 2015-03-26: Novo Nordisk Decided to Resubmit NDA's for Tresiba, Ryzodeg in US

Financial news for NVO dated on 2015-03-25: Novo Nordisk A/S: Novo Nordisk Completes Phase 3a Trials Comparing Faster-Acting Insulin Aspart With NovoRapid in people with type 1 and type 2 diabetes

Financial news for NVO dated on 2015-03-24: Novo Nordisk Receives EC Approval for Saxenda for Treatment of Obesity

Financial news for NVO dated on 2015-03-20: Stocks Hitting 52-Week Highs

Financial news for NVO dated on 2015-02-20: Novo Nordisk Announces Positive Phase 2 Trial Results, Shares Spike Higher

Financial news for NVO dated on 2015-02-20: Morning Market Gainers

Financial news for NVO dated on 2015-02-20: Friday #PreMarket Movers: Arista Networks Up, CollabRx Down

Financial news for NVO dated on 2015-02-20: Benzinga's Top #PreMarket Gainers

Financial news for NVO dated on 2015-02-20: Novo Nordisk Announces Positive Results For Phase 2 Trial With Oral Semaglutide In People With Type 2 Diabette

Financial news for NVO dated on 2015-02-20: Novo Nordisk Announces Positive Phase 2 Trial Results With Oral Semaglutide in People With Type 2 Diabetes

Financial news for NVO dated on 2015-02-13: Simons-Founded Renaissance Technologies Buys Apple, Closes Facebook, Trims McDonald's In Q4

Financial news for NVO dated on 2015-02-09: Novo Nordisk to Seek IPO of NNIT on NASDAQ OMX Copenhagen

Financial news for NVO dated on 2015-01-30: Novo Nordisk Posts Higher Profit

Financial news for NVO dated on 2015-01-30: Earnings Scheduled For January 30, 2015

Financial news for NVO dated on 2015-01-28: Commerbank Downgrades Novo-Nordisk to Hold

Financial news for NVO dated on 2015-01-22: Novo Nordisk Announces Positive Opinion from European Regulatory Authorities for Saxenda

Financial news for NVO dated on 2015-01-14: 5 Obesity Stocks Investors Are Watching

Financial news for NVO dated on 2014-12-18: UPDATE: Xencor is Eligible to Receive Up to \$175M in Upfront, Other Payments

Financial news for NVO dated on 2014-12-18: Xencor, Novo Nordisk Report Discovery Collaboration for Xencor's XmAb Bispecific, Immune Inhibitor Technologies

Financial news for NVO dated on 2014-12-08: How To Profit From The Obesity Epidemic

Financial news for NVO dated on 2014-12-04: A Look At 4 ETFs From The 4 'Least Corrupt' Countries

Financial news for NVO dated on 2014-10-30: Top Performing Industries For October 30, 2014

Financial news for NVO dated on 2014-10-30: Novo Nordisk Posts Rise In Profit

Financial news for NVO dated on 2014-10-24: Novo Nordisk Says Receives Subpoena from US Attorney, Requesting Documents Regarding Potential Manufacturing Issues Within Certain Production Units in Kalundborg, Denmark

Financial news for NVO dated on 2014-10-13: Top 4 NYSE Stocks In The Drug Manufacturers-Other Industry With The Highest Revenue

Financial news for NVO dated on 2014-10-01: 3 Companies Helping To Keep Diabetes Rates Lower

Financial news for NVO dated on 2014-08-11: Top 4 NYSE Stocks In The Drug Manufacturers-Other Industry With The Highest Dividend Yield

Financial news for NVO dated on 2014-07-31: Top 4 NYSE Stocks In The Drug Manufacturers-Other Industry With The Highest EPS

Financial news for NVO dated on 2014-07-07: FDA Has Okayed Novo Nordisk's Novoseven RT for Treatment of Glanzmann's - Bloomberg

Financial news for NVO dated on 2014-06-27: Top 4 Stocks In The Drug Manufacturers-Other Industry With The Highest Dividend Yield

Financial news for NVO dated on 2014-06-23: Novo Nordisk Announces DKK 15Bn Buyback

Financial news for NVO dated on 2014-05-22: Novo Nordisk Says Last Year's Investigation Has Ended, Saw No Increased Frequency of Inspections in China - Bloomberg

Financial news for NVO dated on 2014-05-12: Google Celebrates Dorothy Hodgkin & Her Contributions To Chemistry

Financial news for NVO dated on 2014-03-21: Novo Nordisk Confirms Tresiba, Victoza Receive Positive Opinions from CHMP for Label Updates

Financial news for NVO dated on 2014-03-20: Citi Added Shares of Novo Nordisk to European 'Focus List'

Financial news for NVO dated on 2014-03-19: UPDATE: Novo Nordisk Reports Results from First Phase 3 Trial with N8-GP

Financial news for NVO dated on 2014-03-19: Novo Nordisk Reports Results from First Phase 3 Trial with N8-GP

Financial news for NVO dated on 2014-03-10: Top 4 NYSE Stocks In The Drug Manufacturers-Other Industry With The Highest EPS

Financial news for NVO dated on 2014-02-25: European ETFs Flying Under The Radar

Financial news for NVO dated on 2014-02-25: Bank of America Upgrades Novo Nordisk A/S to Buy

Financial news for NVO dated on 2014-02-24: JP Morgan Upgrades Novo Nordisk A/S to Overweight

Financial news for NVO dated on 2014-02-14: Top 4 NYSE Stocks In The Drug Manufacturers-Other Industry With The Highest Operating Margin

Financial news for NVO dated on 2014-01-31: Swedbank Upgrades Novo Nordisk A/S to Buy

Financial news for NVO dated on 2013-12-03: Benzinga's Volume Movers

Financial news for NVO dated on 2013-11-01: Novo Nordisk Receives FDA Approval for Novolog Flextouch

Financial news for NVO dated on 2013-11-01: Swedbank Downgrades Novo Nordisk A/S to Neutral

Financial news for NVO dated on 2013-10-30: Novo Nordisk Initiates European Share Buyback

Financial news for NVO dated on 2013-10-25: Time To Consider Investing In Scandinavia (EWD, EFNL, NORW, EDEN, GXF)

Financial news for NVO dated on 2013-09-26: Bloomberg Reporting Novo Nordisk Chief Scientist Thomsen Says In Talks with All US Pharmacy Price Cuts in US

Financial news for NVO dated on 2013-09-16: Barclays Upgrades Novo Nordisk A/S to Overweight

Financial news for NVO dated on 2013-09-06: Benzinga's Top Downgrades

Financial news for NVO dated on 2013-09-06: Swedbank Downgrades Novo Nordisk A/S to Buy

Financial news for NVO dated on 2013-09-04: Top 4 Large-Cap Stocks In The Drug Manufacturers-Other Industry With The Highest Cash

Financial news for NVO dated on 2013-08-21: Novo Nordisk Wins US FDA Clearence for Novopen Echo

Financial news for NVO dated on 2013-08-02: Weekly Preview: Earnings Season Nears The End, China in Focus

Financial news for NVO dated on 2013-07-01: Benzinga's Volume Movers

Financial news for NVO dated on 2013-06-24: Helvea Upgrades Novo Nordisk A/S to Buy

Financial news for NVO dated on 2013-06-19: S&P Upgrades Novo Nordisk from A+ to AA-; Outlook Stable

Financial news for NVO dated on 2013-06-19: Exane Downgrades Novo Nordisk A/S to Underperform

Financial news for NVO dated on 2013-06-18: Novo Nordisk: US Appeals Court Affirms 2001 District Court Decision

Financial news for NVO dated on 2013-06-18: Novo Nordisk Says US Court Rules Against it in Patent Case

Financial news for NVO dated on 2013-06-18: US Court Rules Novo Nordisk Patent Claim on Prandin Invalid

Financial news for NVO dated on 2013-06-17: Benzinga's Top Pre-Market Losers

Financial news for NVO dated on 2013-06-17: Benzinga's Top Downgrades

Financial news for NVO dated on 2013-06-17: Bank of America Downgrades Novo Nordisk A/S to Neutral

Financial news for NVO dated on 2013-06-12: FDA Says Considering New Study of Incretin Mimetic Diabetes Drug, Says May Need to Look for Cancer-Link Patterns

Financial news for NVO dated on 2013-06-11: Handelsbanken Upgrades Novo Nordisk A/S to Buy

Financial news for NVO dated on 2013-05-24: Natixis Upgrades Novo Nordisk A/S to Buy

Financial news for NVO dated on 2013-05-01: Novo Nordisk Posts 28% Rise In Q1 Profit, Lifts Forecast

Financial news for NVO dated on 2013-04-16: Swedbank Upgrades Novo Nordisk A/S to Buy

Financial news for NVO dated on 2013-03-19: Novo Receives US FDA Orphan Drug Designation from Hemophilia B Treatment

Financial news for NVO dated on 2013-03-18: JP Morgan Downgrades Novo Nordisk A/S to Underweight

Financial news for NVO dated on 2013-02-27: These ETFs Have Moving Average Problems

Financial news for NVO dated on 2013-02-12: Nomura Upgrades Novo Nordisk A/S to Buy

Financial news for NVO dated on 2013-02-11: Denmark ETF Decked by Novo Nordisk's Slide

Financial news for NVO dated on 2013-02-11: Morning Market Losers

Financial news for NVO dated on 2013-02-11: Benzinga's Top Pre-Market Losers

Financial news for NVO dated on 2013-02-11: Kepler Downgrades Novo Nordisk A/S to Hold

Financial news for NVO dated on 2013-02-11: Novo Nordisk Shares Plunge Following CRL in US for Tresiba, Ryzodeg

Financial news for NVO dated on 2013-02-11: Natixis Downgrades Novo Nordisk A/S to Neutral

Financial news for NVO dated on 2013-02-11: Top 4 NYSE Stocks In The Drug Manufacturers-Other Industry With The Highest Dividend Yield

Financial news for NVO dated on 2013-02-05: Novo Nordisk Receives FDA Warning Letter Related to Danish Plant Inspection

Financial news for NVO dated on 2013-01-29: Novo Spokesperson Says Will Introduce Tresiba in Some EU Countries in First Half - Bloomberg

Financial news for NVO dated on 2013-01-28: Goldman Sachs Names Novo Nordisk to Conviction Buy List

Financial news for NVO dated on 2012-11-16: Top 4 NYSE Stocks In The Drug Manufacturers-Other Industry With The Highest Cash

Financial news for NVO dated on 2012-11-08: FDA Panel Votes 8-4 to Back Nova Nordisk's Tresiba Approval

Financial news for NVO dated on 2012-11-08: FDA Panel Says Novo's Degludec Insulin Needs CV Trial, Votes 12-0

Financial news for NVO dated on 2012-11-08: UPDATE: FDA Advisory Panel Acting Chairperson Says panel Members Generally Agree that Signal of Cardiovascular Risk Was Seen For Novo Nordisk's Degludec Insulin, and That it "May or May Not Be a Real" Risk -Reuters

Financial news for NVO dated on 2012-11-08: Novo Nordisk Spikes Higher

Financial news for NVO dated on 2012-11-08: FDA Panel Says Signal of Cardiovascular Risk For Novo Nordisk's Degludec Insulin "May or May Not Be Real" -Reuters

Financial news for NVO dated on 2012-11-08: Novo Nordisk Spikes to Highs

Financial news for NVO dated on 2012-11-06: Jefferies & Company Downgrades Novo Nordisk A/S from Buy to Hold

Financial news for NVO dated on 2012-10-31: Novo Nordisk Posts 35% Rise In Q3 Profit, Lifts 2012 Forecast

Financial news for NVO dated on 2012-10-24: Top 4 NYSE Stocks In The Drug Manufacturers-Other Industry With The Highest Operating Margin

Financial news for NVO dated on 2012-10-19: Stocks Hitting 52-Week Highs

Financial news for NVO dated on 2012-09-28: Novo Nordisk Stops Development of Vatreptacog

Financial news for NVO dated on 2012-08-09: Novo Nordisk Posts 29% Surge In Q2 Profit, Lifts Forecast

Financial news for NVO dated on 2012-06-21: Novo Nordisk to Initiate Phase 3 Development of Semaglutide

Financial news for NVO dated on 2012-06-18: Humana and Novo Nordisk Form Partnership to Improve Quality Outcomes for Patients Fighting Diabetes

Financial news for NVO dated on 2012-06-08: Novo Says FDA Delay Due to Huge Size of Data Submitted, FDA Delay on Degludec Doesn't Change Much, Sees No Advisory Committee Based on FDA Talks So Far -Bloomberg

Financial news for NVO dated on 2012-06-04: The Definitive Scandinavian ETF Guide

(EWD, GXF, EDEN)

Financial news for NVO dated on 2012-05-25: Novo Nordisk Gets Positive Opinion on Recombinant Factor XIII from European Regulatory Officials

Financial news for NVO dated on 2012-05-22: Novo Nordisk Announces FDA Approves Levemir(r) for Expanded Use in Children Two to Five Years of Age with Type 1 Diabetes

Financial news for NVO dated on 2012-05-01: Caisson Biotech Enters into Development and License Agreement with Novo Nordisk

Financial news for NVO dated on 2012-04-02: Novo Nordisk

Financial news for NVO dated on 2012-04-02: Novo Nordisk Stock Up on Diabetes, Obesity Drug News

Financial news for NVO dated on 2012-04-02: FDA Approves Levemir(R) Pregnancy Category Change For Women With Diabetes

Financial news for NVO dated on 2012-03-21: St. Jude, Novo Nordisk and Other Health Care Stocks Worth a Look Now

Financial news for NVO dated on 2012-02-02: Novo Nordisk Reports 19% Rise In Q4 Profit, Lifts Forecast

Financial news for NVO dated on 2012-01-31: Escaping Europe's Escapades In The Garden of EDEN

Financial news for NVO dated on 2011-08-31: 9 Option Trades on Dividend Stocks & Gold

Financial news for NVO dated on 2011-08-30: 3 Top Dividend Growth Stocks

Financial news for NVO dated on 2011-05-22: Top Healthcare and Major Drugs stocks to watch- Sector Performance

Financial news for NVO dated on 2011-05-18: GlaxoSmithKline and Isis Pharmaceuticals partnership shouldn't be overlooked as a long-term

Financial news for NVO dated on 2011-04-26: CEOWORLD Top 10 Tech Stocks Winning 52-Week Highs- ABB, IBM, ORCL, NVO, BTI, SAP, ERIC, VMW, ACN and MA

Financial news for NVO dated on 2011-04-11: JP Morgan Downgrades NVO To Neutral

Financial news for NVO dated on 2011-02-22: Portfolio Construction Philosophy

Financial news for NVO dated on 2011-02-14: Mad Money Lightning Round: Cramer Advises Investors To Buy Apple (NVO, FNSR, ARG, AAPL, OH)

Financial news for NVO dated on 2011-01-27: Cost Control Helps Amylin Cut Loss - Analyst Blog

Financial news for NVO dated on 2011-01-27: Cost Control Helps Amylin Cut Loss - Analyst Blog

Financial news for NVO dated on 2011-01-25: Earnings Preview: Eli Lilly - Analyst Blog

Financial news for NVO dated on 2011-01-25: Earnings Preview: Eli Lilly - Analyst Blog

Financial news for NVO dated on 2011-01-25: Goldman Ups NVO To Buy

Financial news for NVO dated on 2011-01-20: MannKind in Jeopardy - Analyst Blog

Financial news for NVO dated on 2011-01-20: MannKind in Jeopardy - Analyst Blog

Financial news for NVO dated on 2011-01-14: Deutsche Bank Downgrades NVO To Sell

Financial news for NVO dated on 2010-12-30: Top 4 Stocks In The Drug Manufacturers-Other Industry With The Highest Dividend Yield (TPI, RELV, TEVA, NVO)

Financial news for NVO dated on 2010-12-29: Novo Presents Positive Insulin Data - Analyst Blog

Financial news for NVO dated on 2010-12-29: Novo Presents Positive Insulin Data - Analyst Blog

Financial news for NVO dated on 2010-12-13: Loss at BIOD Narrower than Expected - Analyst Blog

Financial news for NVO dated on 2010-12-13: Top Funds Bet on Less Well-Known Trends

Financial news for NVO dated on 2010-12-13: Loss at BIOD Narrower than Expected - Analyst Blog

Financial news for NVO dated on 2010-12-10: Benzinga's Top Upgrades (BRCM, NVO, ARG, PG)

Financial news for NVO dated on 2010-12-10: Citigroup Upgrades NVO To Buy

Financial news for NVO dated on 2010-12-03: Merck Strikes Deal with SmartCells - Analyst Blog

Financial news for NVO dated on 2010-12-03: Merck Strikes Deal with SmartCells - Analyst Blog

Financial news for NVO dated on 2010-11-18: Morgan Stanley Downgrades NVO To Equal Weight

Financial news for NVO dated on 2010-11-12: Zacks Analyst Blog Highlights: Lions Gate Entertainment, Amylin Pharmaceuticals, Amylin Pharmaceuticals, Eli Lilly, Alkermes and Novo Nordisk - Press Releases

Financial news for NVO dated on 2010-10-28: JP Morgan Upgrades NVO To Overweight

Financial news for NVO dated on 2010-10-20: Stocks Rip Higher (SPY, DAL, AMR, NVO, URI)

Financial news for NVO dated on 2010-10-20: Top Performing Industries For October 20 (DAL, NVO, SHZ, CNTY)

Financial news for NVO dated on 2010-10-20: Novo Nordisk Skyrocketing (NVO)

Financial news for NVO dated on 2010-10-19: Two Exceptionally Weak Stocks Today (CBST, NVO)

Financial news for NVO dated on 2010-10-19: Societe Generale Upgrades NVO To Hold

Financial news for NVO dated on 2010-10-04: Novo Nordisk to Invest \$73m in Expansion

Financial news for NVO dated on 2010-09-21: BMJ's Diabetes Candidate Encourages - Analyst Blog

Financial news for NVO dated on 2010-08-09: Revenues Dip at Alkermes - Analyst Blog

Financial news for NVO dated on 2010-06-07: Top 5 Large-Cap NYSE Stocks In The Healthcare Sector With The Highest Return On Equity (GSK, LLY, AZN, ACL, NVO)

Financial news for NVO dated on 2010-03-31: NVO Initiated With Hold

Financial news for NVO dated on 2010-03-03: Top 5 NYSE Stocks In the Healthcare Sector With The Highest ROA (NVO, ACL, HLF, AZN, VAR)

Financial news for NVO dated on 2010-02-12: Portfolio Tweak

Financial news for NVO dated on 2010-01-26: Stocks That Created New 52-Week Highs (AMLN, CNXT, GOODO, NRGF, INSW)

Financial news for NVO dated on 2010-01-26: Benzinga's Volume Movers (VLTR, AMLN, PRXL, ICLR, ZION)

Financial news for NVO dated on 2010-01-26: FDA Approval For Diabetes Drug Lifts Novo Shares (NVO, AMLN, LLY)

Financial news for NVO dated on 2010-01-16: Going Nordic In Search Of ETF Opportunities

Financial news for NVO dated on 2010-01-15: Benzinga's Top Downgrades (PAYX, NVO, TEVA, PVA, PRSC)

Financial news for NVO dated on 2009-12-30: Benzinga's News Roundup (SNTS, MRVL, NVO, AET, CIEN, NVDA)

Financial news for NVO dated on 2009-08-17: Novo Nordisk A/S: Transaction in Own Shares

Financial news for NVO dated on 2009-08-16: 16 Companies that Raised Dividends 10% or More for the Last Nine Years

Financial news for NVO dated on 2009-08-07: Transaction in Own Shares

Financial news for NVO dated on 2009-08-07: Novo Nordisk A/S - Transaction in Own Shares

Financial news for NVO dated on 2009-08-07: Novo Nordisk A/S - Transaction in Own Shares

Financial news for NVO dated on 2009-07-27: Liraglutide Lowered Blood Sugar and Weight in African Americans With Type 2 Diabetes, Phase 3 Data Showed